Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: A case report

Oncologist

Volumn 15, Issue 2, 2010, Pages 142-145

  Perboni, Giorgio ^a   Costa, Paolo ^a   Fibbia, Giovanni Carlo ^a   Morandini, Barbara ^a   Scalzini, Alfredo ^a   Tagliani, Alberto ^a   Cengarle, Rita ^a   Aitini, Enrico ^a  

^a CARLO POMA HOSPITAL   (Italy)

Author keywords

Coinfection; HCV; Hepatocellular carcinoma; HIV; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; EMTRICITABINE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; RITONAVIR; SORAFENIB; TENOFOVIR DISOPROXIL;

ADULT; ADVANCED CANCER; ANTIVIRAL THERAPY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CASE REPORT; CD4 LYMPHOCYTE COUNT; DIARRHEA; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERTENSION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN MANIFESTATION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; VIREMIA;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER NEOPLASMS; MALE; PYRIDINES; RISK FACTORS;

EID: 77649163829     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0010     Document Type: Article

References (26)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
2. Bonacini M, Govindarajan S, Blatt LM et al. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999;6:203-208.
3. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
4. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001;183:1112-1115.
5. Bhaskaran K, Hamouda O, Sannes M et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-59.
6. Herida M, Mary-Krause M, Kaphan R et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21:3447-3453.
7. Sulkowski M. Hepatocellular carcinoma in HIV-infected patients comes of age: The convergence of epidemiology and treatment effectiveness. J Hepatol 2009;50:655-658.
8. Clifford GM, Rickenbach M, Polesel J et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008;22:2135-2141.
9. Bräu N, Fox RK, Xiao P et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. J Hepatol 2007;47:527-537.
10. Murillas J, Del Río M, RieraMet al. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med 2005;16:113-115.
11. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected patient. Clin Liver Dis 2003;7:179-194.
12. Giordano TP, Kramer JR, Souchek J et al. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: A cohort study, 1992-2001. Arch Intern Med 2004;164:2349-2354.
13. Patel P, Hanson DL, Sullivan PS et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728-736.
14. Mocroft A, Phillips AN, Gatell J et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking antiretroviral therapy: An observational cohort study. Lancet 2007;370:407-413.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
16. Roland ME, Barin B, Carlson L et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008;8:355-365.
17. de Vera ME, Dvorchik I, Tom K et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006;6:2983-2993.
18. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007;14:371-386.
19. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
20. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
21. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-1327.
22. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-477.
23. Bayer HealthCare Pharmaceuticals Inc. Nexavar® [package insert]. Available at http://berlex.bayerhealthcare.com/html/products/pi/Nexavar-PI.pdf, accessed October 20, 2009.
24. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: Treatment considerations and research outlook. Curr Opin Oncol 2009;21:445-454.
25. Lathia C, Lettieri J, Cihon F et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-692.
26. Mounier N, Katlama C, Costagliola D et al. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol 2009;72:10-20.